Is NCT05123482 recruiting in Shreveport, LA?

Yes, NCT05123482 is currently recruiting participants at its Shreveport, LA location. This advanced cancer clinical trial is actively enrolling qualified participants.

How do I join the advanced cancer clinical trial in Shreveport?

To join this clinical trial in Shreveport, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Shreveport clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Advanced Cancer Clinical Trial in Shreveport, LA

Who Can Participate

Inclusion Criteria

Age ≥ 18 years

Relapsed/metastatic solid tumors treated with prior adequate standard of care therapy for tumor type and stage of disease or where in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or tolerability to prior therapy.

Measurable disease per RECIST v1.1

Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1

Life expectancy ≥ 12 weeks

Adequate bone marrow, hepatic, and renal function as defined in the protocol Additional Inclusion Criteria For Sub-Study 1 Part A: • Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, ovarian cancer, BTC or endometrial cancer Additional Inclusion Criteria For Sub-Study 1 Part B:

Histologically or cytologically confirmed metastatic or locally advanced and recurrent disease for the respective cohort:

Cohort B1 (Biliary Tract Cancer)

Cohort B2 (Ovarian Cancer)

Cohort B3 (Breast Cancer)

Cohort B4 (Endometrial Cancer)

Cohort B5 (Squamous Non-Small Cell Lung Cancer) Additional Inclusion Criteria For Sub-Study 2 Part A:

Minimum body weight ≥ 30 kg.

Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, ovarian cancer, BTC, endometrial cancer or squamous non-small cell lung cancer. Additional Inclusion Criteria For Sub-Study 3 Part A:

Minimum body weight ≥ 30 kg (for participants enrolled in cohorts including rilvegostomig only).

Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, endometrial cancer or squamous non-small cell lung cancer.

Participants must have progressed following at least one but no more than 3 prior lines of treatment for metastatic or relapsed disease and have no satisfactory alternative treatment option as judged by the Investigator. Key

Exclusion Criteria

Treatment with any of the following:

Nitrosourea or mitomycin C within 6 weeks prior to the first dose of study treatment

Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 28 days (whichever is shorter) prior to the first dose of study treatment

Any other anticancer treatment within the following time periods prior to the first dose of study intervention:

Cytotoxic treatment: 21 days

Non-cytotoxic drugs: 21 days or 5 half-lives (whichever is shorter)

Biological products including immuno-oncology agents: 28 days

Spinal cord compression or a history of leptomeningeal carcinomatosis.

Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids at a dose of \> 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study.

Active infection including tuberculosis and HBV, HCV or HIV

History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.

Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses

Participants with any of the following cardiac criteria:

History of arrhythmia which is symptomatic or requires treatment (NCI CTCAE v5.0 Grade 3); symptomatic or uncontrolled atrial fibrillation, or asymptomatic sustained ventricular tachycardia.

Uncontrolled hypertension.

Acute coronary syndrome/acute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention, or coronary artery bypass grafting within 6 months.

History of brain perfusion problems (eg, carotid stenosis) or stroke, or transient ischemic attack in the last 6 months prior to screening.

Symptomatic heart failure (NYHA class ≥ 2).

Prior or current cardiomyopathy.

Severe valvular heart disease.

Mean resting QTcF \> 470 msec.

Risk factors for QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age.

Patients with history of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML (as determined by prior diagnostic investigation) Additional Exclusion Criteria For Sub-Study 2 Part A:

Thromboembolic event within 3 months before the first dose of study intervention - No longer applicable per amendment 7

Experienced a toxicity that led to permanent discontinuation of prior immunotherapy.

Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.

History of organ transplant Additional Exclusion Criteria For Sub-Study 2 Part B • Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.) Additional Exclusion Criteria For Sub-Study 3 Part A:

Concomitant use of medications or herbal supplements known to be strong cytochrome P (CYP) 3A4 inducers/inhibitors.

Any history of persisting (\> 2 weeks) severe cytopenia due to any cause

Patients with any known predisposition to bleeding

Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of saruparib.

Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.) Additional Exclusion Criteria For Sub-Study 4 Part A:

Patients have received prior therapy with AZD9574 or more than 1 prior line of any other PARPi-based regimen

Concomitant use of medications or herbal supplements known to be strong cytochrome P (CYP) 3A4 inducers/inhibitors.

Previous treatment with rilvegostomig for the cohort treated with rilvegostomig

Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Shreveport?

Yes, this clinical trial (NCT05123482) has an active research site in Shreveport, LA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Cancer Treatment Options in Shreveport, LA

If you're searching for advanced cancer treatment options in Shreveport, LA, this clinical trial (NCT05123482) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Shreveport research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced advanced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced cancer clinical trials near you to find additional studies recruiting in your area.

Advanced Cancer Clinical Trial in Shreveport, LA

Expert Care in Shreveport

IRB Approved

No-Cost Care

Apply for This Shreveport Location

Why Participate?

Simple Process

About This Advanced Cancer Study in Shreveport